Efficacy and safety of switching basal insulin to insulin glargine 300 U/ <scp>mL</scp> in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo <scp>T2DM</scp> study
Switching BI to Gla-300 from a BOTplus or MDI regimen with prior insulin Gla-100, IDeg, IDet, or NPH improved glycaemic control in participants with inadequately controlled T2DM over 12 months without increasing hypoglycaemia risk or weight gain.
Authors
- Helmut Anderten
- Katrin Pegelow (ORCID: https://orcid.org/0000-0001-9002-5305)
- Martin Pfohl
- Stefan Pscherer
- Andreas Fritsche
- Jochen Seufert
- Henry Y. Han
Institutions
- University of Hildesheim (DE)
- University Medical Center Freiburg (DE)
- Bethesda Hospital (IN)
- Sophien-und Hufeland Klinikum (DE)
- Sanofi (Germany) (DE)
- STZ eyetrial (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1111/dom.70417
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Sanofi-Aventis Deutschland